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Abstract 28 
Childhood-onset craniopharyngiomas are rare embryonal malformations of low-grade 29 
histological malignancy. Novel insights in molecular pathogenesis of human 30 
adamantinomatous craniopharyngioma has started to be unveiled offering the possibility of 31 
testing novel treatments targeting pathogenic pathways. Hypothalamic involvement and/or 32 
treatment-related lesions result in impaired physical and social functionality and severe 33 
neuroendocrine sequelae. Quality of survival in craniopharyngioma with hypothalamic 34 
involvement is impaired by severe obesity, physical fatigue, and non-optimal psychosocial 35 
development. Patients with craniopharyngioma involving hypothalamic structures show 36 
reduced 20-years overall survival, whereas overall and progression-free survival rates are not 37 
related to the degree of surgical resection. Irradiation is effective in prevention of tumor 38 
progression and recurrence. For favorably localized craniopharyngiomas, the preferred 39 
treatment of choice is an attempt at complete resection with preservation of visual, 40 
hypothalamic, and pituitary function. For unfavorably localized tumors with close proximity 41 
to optical and/or hypothalamic structures a radical neurosurgical strategy attempting complete 42 
resection is not recommended in order to prevent severe sequelae. As expertise has been 43 
shown to have impact on post-treatment morbidity, medical societies should establish criteria 44 
of adequate professional expertise for the treatment of craniopharyngioma. Based on these 45 
criteria, health authorities should organize the certification of centers of excellence authorized 46 
for treatment and care of patients with this chronic disease. 47 
 48 
Key words: craniopharyngiomas, hypothalamus, irradiation, neurosurgery, obesity, quality of 49 
life. 50 
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Introduction 52 
For decades gross-total resection was the preferred treatment option in childhood-onset 53 
craniopharyngioma (CP), assuming that radical strategies at the time of initial diagnosis and 54 
treatment would result in the cure of CP.  55 
Recent reports on long-term prognosis, novel neurosurgical and radiooncological treatment 56 
approaches, and molecular genetics provide new insight into more risk-adapted treatment in 57 
CP in order to prevent severe sequelae such as hypothalamic syndrome and obesity1-4.  58 
 59 
Epidemiology 60 
CPs are rare, with an incidence of 0.5 to 2 cases per million persons per year 5. A bimodal age 61 
distribution has been shown, with peak incidence rates in children of ages 5 to 14 years and 62 
adults of ages 50 to 74 years 6, 7.  63 
 64 
Clinical presentation and diagnostics 65 
The diagnosis of childhood-onset CP is often made late 8 ⎯ sometimes years after initial 66 
appearance of symptoms ⎯ with a clinical picture often dominated by manifestations of 67 
intracranial pressure Further primary manifestations are endocrine deficits (52–87%) and 68 
visual impairment (62–84%). Hormonal deficits are frequently caused by disturbances to the 69 
hypothalamic–pituitary axes that affect growth hormone secretion (75%), gonadotropins 70 
(40%), thyroid-stimulating hormone (TSH) (25%), and adrenocorticotropic hormone (ACTH) 71 
(25%) 9. 72 
In a study of Hoffmann et al.10, median duration of history was 6 mo (range: 0.1–108 mo) and 73 
correlated positively with age at diagnosis. Tumour size, hypothalamic involvement, degree 74 
of resection, and BMI at diagnosis were not related to duration of history. In multivariate 75 
analysis adjusted for age at diagnosis, only hydrocephalus was found to have a significant 76 
influence on duration of history. Visual and neurological deficits were associated with larger 77 
initial tumour size and impaired 10-yr OS. Weight gain and growth failure were observed 78 
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with longest duration of history. PFS and functional capacity were not related to any specific 79 
symptom. Endocrine deficits at diagnosis were associated with long duration of history10.  80 
With regards to the anatomical landmarks of help to achieve a precise preoperative MRI 81 
diagnosis of the accurate topographical relationships between the tumor and the 82 
hypothalamus/optic chiasm/third ventricle some studies have identified important signs to be 83 
considered 11, 12. The solid mammillary bodies are grossly displaced/distorted by the lesions 84 
involving the hypothalamus but do not become invaded by the tumor as a rule. The position 85 
and distortion of the mammillary bodies can be identified preoperatively and helps to predict 86 
the relative position and adherence of the distorted hypothalamus 13. The use of heavily T2-87 
weighted MR 14 and FIESTA MRI sequences 15 allow an optimal identification of the brain-88 
CP interphase as well as the relative position of the hypothalamus both essential for the 89 
planning of surgical/radiotherapy treatments. 90 
 91 
Molecular pathology of adamantinomatous CP 92 
It is now well established that the vast majority, very likely all, of the human 93 
adamantinomatous CP tumours carry over-activating mutations in the gene encoding beta-94 
catenin (CTNNB1) 16-19. Of note, the papillary form of CP, which usually present in the 95 
elderly, carry BRAF p.V600E mutations and show distinct methylation profiles, indicating 96 
that adamantinomatous CP and papillary CP have two different molecular identities 19, 20. 97 
Recently, the coexistence of BRAF p.V600E and CTNNB1 mutations have been reported in 98 
one case of adamantinomatous CP 21. Further molecular analyses are required to identify 99 
which, if any, other recurrent mutations are present in human adamantinomatous CP in 100 
addition to those in CTNNB1. Nonetheless, it seems likely that human adamantinomatous CP 101 
is a tumour with a low mutation burden.  102 
 103 
Most of the identified mutations in adamantinomatous CP lie in regulatory amino aids 104 
encoded by exon 3 of the CTNNB1 gene 22. The molecular consequence of such mutations is 105 
the expression of a mutant form of beta-catenin with increased degradation resistance, 106 
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resulting in the accumulation of beta-catenin and subsequent activation of the WNT pathway. 107 
Confirming this, human adamantinomatous CP contains cells with nucleo-cytoplasmic 108 
accumulation of beta-catenin, which are either dispersed throughout the tumours or grouped 109 
in whorls of cells, termed cell clusters 23-25. These clusters are not present in any other 110 
pituitary tumour and represent a histological hallmark of human adamantinomatous CP 26. 111 
Tumour cells including cell clusters, activate the WNT pathway, as evidenced by the 112 
expression of gene targets such as AXIN2 or LEF1 23, 24. 113 
 114 
Gene expression profiling studies of human adamantinomatous CP have been performed to 115 
better characterize its pathogenesis downstream of the activation of the WNT/beta-catenin 116 
signaling 20, 27. These studies have revealed several pathways that are deregulated in these 117 
tumours as a consequence of the over-activation of the WNT/beta-catenin pathway (Figure 118 
1). Many of the deregulated pathways are targetable with specific inhibitors, which could 119 
potentially offer new therapeutic opportunities. The next logical step is to perform well-120 
designed pre-clinical studies to determine the function of these pathways in the biology of 121 
adamantinomatous CP. These pre-clinical studies will inform whether a particular pathway 122 
has anti- or pro-tumorigenic effects, and therefore, whether therapies should either aim to 123 
inhibit or promote its activity. This knowledge of adamantinomatous CP biology should 124 
facilitate the generation of human clinical trials specifically designed to assess the efficacy of 125 
particular drugs against human adamantinomatous CP. In our view, robust pre-clinical data is 126 
imperative before translating findings into the clinic, as some of the deregulated pathways 127 
may have functions that are tumour context dependent, and therefore, their therapeutic value 128 
needs to be assessed specifically in each tumour. Nonetheless, as in any targeted therapy, drug 129 
resistance may arise, although the low mutational burden of adamantinomatous CP tumours 130 
may be prevent the acquisition of such resistances.  131 
  132 
Pre-clinical models of human adamantinomatous CP 133 
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There have been several attempts to establish pre-clinical models of human ACP, from 134 
primary cell cultures to genetically engineered mouse models (GEMMs) and patient-derived 135 
xenografts (PDXs).  136 
 137 
Primary cells from human adamantinomatous CP samples have been isolated and used for 138 
diverse studies to assess the effects of the WNT/beta-catenin, Claudin-1 and EGF pathways in 139 
migration and invasion 28-30. Although these experiments are encouraging and informative, no 140 
molecular profiling of these tumour cells has been carried out. In addition, these cells cannot 141 
be easily cultured and passaged. Further characterization of these cells (e.g. the degree of 142 
molecular similarity to the human tumours) and optimization of the culture conditions are 143 
required to achieve the maximum potential of this in vitro cell model.  144 
 145 
A genetically engineered mouse model (GEMM) has been generated by expressing a mutant 146 
form of beta-catenin that is resistant to degradation in undifferentiated embryonic precursors 147 
of the pituitary gland (i.e. the embryonic adamantinomatous CP mouse model) 23. 148 
Interestingly, when oncogenic beta-catenin is expressed in committed progenitors (e.g. Pit1-149 
expressing cells) or hormone-producing cells (e.g. somatotrophs), no tumours develop, 150 
suggesting that only undifferentiated progenitors provide the cellular context required for 151 
tumours to form. This oncogenic beta-catenin is functionally equivalent to that identified in 152 
human adamantinomatous CP, therefore the molecular aetiology in this GEMM is similar to 153 
human adamantinomatous CP. 154 
 155 
Several histological and molecular features are conserved between the mouse and human 156 
tumours. As observed in humans, mouse tumours show cystic and solid components, are 157 
synaptophysin-negative and do not express hormones. The pituitary gland of these mice at 158 
birth and early postnatal stages show the presence of clusters with nucleo-cytoplasmic 159 
accumulation of beta-catenin, which typifies human adamantinomatous CP. However, murine 160 
tumours do not show a clear palisading epithelium, wet keratin or any sign of calcification, all 161 
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common features in human tumours. Likewise, tumours do not infiltrate the brain or visual 162 
pathways in the mouse, but this is a common finding in humans. Despite the histological 163 
differences, molecular analyses of the mouse tumours have predicted the up-regulation of 164 
several gene pathways in the human, which have been later confirmed in human studies (e.g. 165 
SHH and C-X-C motif chemokine receptor 4, CCR4) 31-33. Therefore, this model shows 166 
similar molecular aetiology and pathogenesis to human adamantinomatous CP, but there are 167 
species-specific differences that need to be considered 34. 168 
 169 
A second GEMM has been obtained by targeting the expression of oncogenic beta-catenin 170 
into adult SOX2-positive pituitary stem cells (i.e. the inducible mouse adamantinomatous CP 171 
model) 35. The resulting tumours also show a degree of resemblance with human 172 
adamantinomatous CP; specifically, these murine tumours are non-secreting and have beta-173 
catenin-accumulating cell clusters. However, as in the embryonic model, these tumours lack 174 
some common histological features of the human tumours (e.g. palisading epithelium and wet 175 
keratin) and do not infiltrate the brain or visual pathways. 176 
 177 
Importantly, these GEMMs have revealed that paracrine activity of mutated progenitors/stem 178 
cells may be critical in controlling growth and behavior of adamantinomatous CP, a concept 179 
that could have further implications in the cancer field 36. Specifically, Sox2-positive pituitary 180 
stem cells have been targeted to express oncogenic beta-catenin simultaneously with a 181 
fluorescent reporter that allows genetic tracing of the descendants of targeted Sox2 cells. 182 
These experiments have revealed that the murine tumours are not derived from the targeted 183 
Sox2-positve cells, instead, these mutant Sox2-positive cells proliferate transiently whilst 184 
accumulating beta-catenin, then stop dividing but persist, generating the beta-catenin-185 
accumulating cell clusters. Since the mutated cells stop proliferating it is important to ask: 186 
how do the tumours form? Molecular profiling of the murine clusters has demonstrated the 187 
expression of a plethora of signaling molecules including proliferative and survival signals as 188 
well as inflammatory cytokines and chemokines, which are hypothesized to generate a pro-189 
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tumorigenic microenvironment that results in transformation of a neighboring cell (Figure 2). 190 
This paracrine model has been shown to be relevant in other murine neoplasia such as 191 
hepatocellular carcinoma and leukaemia 36, 37.  192 
 193 
PDXs have also been developed, by transplanting pieces of biopsies from human 194 
adamantinomatous CP either subcutaneously 38, 39 or intracranially 40 into immunosuppressed 195 
mice. In these models, the cellular architecture of the original tumour is maintained, therefore 196 
offering a suitable model to test the effects of potential therapies and understand further the 197 
biology of these neoplasias. Using the intracranial model, it has been proposed that the 198 
paracrine activities of the clusters may be critical in controlling the infiltrative behavior of 199 
human adamantinomatous CP 40, a finding that is compatible with the 3D structure of human 200 
adamantinomatous CP recently reported 41. These are certainly very promising tools, but have 201 
also some limitations. For instance, the tumours develop in an immunosuppressed 202 
environment, when inflammation is likely to play a critical role in the pathogenesis of these 203 
neoplasias 27, 31, 42, 43. In addition, the rareness of human adamantinomatous CP makes it 204 
challenging to obtain biopsies and the slow growth of the engrafted tumours may make any 205 
analysis more difficult (Table 1).  206 
 207 
In conclusion, there are several available pre-clinical models for human adamantinomatous 208 
CP, each of them accompanied by advantages and disadvantages. We anticipate that the 209 
combined use of some or all of these models may be required to assess the pathogenicity of 210 
particular pathways and the potential therapeutic efficacy of selective drugs.   211 
 212 
Surgery 213 
The surgical management of CP in children remains one of the more controversial topics in 214 
pediatric neurosurgery. Theoretically, the benign histology implies that total surgical excision 215 
should be sufficient to provide a cure.  216 
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In the past: Large pediatric surgical series showed their surgical success in radically resecting 217 
CPs 44-49. However, the associated mortality (up to 50% at 10 years) and high rate of 218 
recurrence despite surgical clearance (up to 50% in some series) became apparent and it has 219 
been widely established, that in certain cases total excision may lead to unacceptable 220 
hypothalamic injury 50-53.  221 
Present : The state-of-the-art in the surgical management of CP is now turning to multi-222 
modality treatment strategies (combination surgery and radiotherapy) aiming to limit 223 
morbidity. In the beginning of the 2000’s, the Necker’s neurosurgical team proposed that the 224 
treatment strategy may be adapted according to the degree of hypothalamic involvement as 225 
shown by the pre-operative MRI 53, 54. Recent technical advances such as neuronavigation, 226 
endoscopy (combined with microscpic resection for transcranial approaches or solely for 227 
endonasal transsphenoidal approaches) and per-operative imaging may help the neurosurgeon 228 
to safely remove the CP, preserving the hypothalamus structures. 229 
 230 
Primary CP management is tailored to presentation.  231 
In emergency: In some cases with recent signs of raised intracranial pressure (ICP) and/or 232 
visual loss, surgical decompression in emergency is required. In those cases, the clinical signs 233 
are mainly linked to hydrocephalus due to a CP cyst developed in the third ventricle impairing 234 
the CSF pathways. A ventriculoperitoneal shunt should be avoided (risk of dysfunction and 235 
hyperdrainage that can prevent a further safe transcallosal approach) and it is recommended to 236 
decompress the cyst by placement of a catheter and eventually an ommaya reservoir to allow 237 
repeated aspiration. The catheter can be placed during an open surgery (rare), a stereotactic 238 
procedure of preferably an endoscopic approach. Importantly, the decompression of a cyst 239 
may help in refining the risk grade 55.  240 
For cystic CP, intracystic therapies can be performing after permeability test done one to two 241 
weeks after the initial surgery (injection of contrast medium in the subcutaneous reservoir). 242 
Radiotherapy agents (Yttrium-90 and Phosphorus-32) or chemotherapy with bleomycin has 243 
had some success but has been associated with neurotoxicity or even death and has not proven 244 
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to be consistently efficacious 56. The most effective intracystic treatment with best benefit risk 245 
ratio seems to be obtained with interferon alpha. However, like for other intracystic therapies, 246 
the effect is limited to the cystic portion with no effect on the solid component and there is no 247 
available data published so far on the PFS after this treatment 56, 57.  248 
Surgery based on the hypothalamus involvement: The neurosurgeon will therefore plan 249 
surgery(ies) according to (1) the goal for a total resection or according to the hypothalamus 250 
involvement (risk grading 0,1,2) (2) location of the tumor and identification of some 251 
anatomical landmarks to choose the best pathway(s). The anatomical landmarks important to 252 
identify before surgery are the length of the optic nerve pathways and the location of the 253 
anterior communicant artery, the sellar diaphragm, the hypothalamic structures (the 254 
mammillary bodies and the shape of the third ventricle floor), the size of the ventricles and 255 
the presence of a septum pellucidum.   256 
- Grade 0: no hypothalamus involvement: most of these cases are developed in the sellar 257 
region, under the sellar diaphragm. An endoscopic endonasal transsphenoidal route is ideal in 258 
these cases and has been uncommonly used in pediatric CP due to their rarity compared to 259 
adults but also to unfavorable anatomic conditions such as small nostrils, non-pneumatized 260 
sphenoid sinus or short intercarotid distance 58.  However, in experienced teams, young 261 
patients’ age does not seem to be an obstacle and more and more publications report the 262 
success of this technique 59-61. Some authors claimed to avoid hypothalamic dysfunction with 263 
endoscopic endonasal transsphenoidal approach 62, 63 although it must be emphasized that the 264 
majority of tumors approached via this route are infra diaphragmatic in location 64. 265 
- Grade 1: the CP is in contact with the hypothalamus that is pushed or compressed, this latter 266 
being still identified on pre-op MRI. In some cases, according to neurosurgeon’s skills and 267 
the extension of the CP, an endoscopic endonasal transsphenoidal approach can be perform or 268 
a transcranial route, which has been traditionally used.  269 
- Grade 2: the hypothalamus is invaded by the CP and cannot be easily identified. The most 270 
frequent transcranial routes are transcallosal, pterional and uni or bilateral subfrontal 271 
approaches. Different approaches can be done in the same patients in case of planned staged 272 
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surgeries to preserve hypothalamic structures. In case of lower displacement of hypothalamic 273 
structures, a transcallosal or a lamina terminalis approach should be preferred. On the 274 
contrary, an upper displacement of these structures should lead to a pterional or subfrontal 275 
approach. As the goal in these CP group is to preserve the invaded hypothalamus, the 276 
endoscopic endonasal transsphenoidal route is not recommended in these children as it may 277 
be difficult, through this approach by endoscope, to anticipate the localization of the 278 
remaining hypothalamus and the perforating arteries. 279 
In fact, many CPs originate primarily within the infundibulum and/or the tuber cinereum and 280 
expands within the hypothalamus itself, representing the subpopulation which associate the 281 
highest adherence, highest recurrence rate and worst outcome 65. Several papers demonstrate 282 
support the need of a hypothalamus-referenced classification of CPs 66-69. About 40% of CPs 283 
in the different series present a predominant involvement of the hypothalamus 70, 71. 284 
  285 
Pediatric CP rare lesions and their surgical treatment is very challenging, thus should be done 286 
in experienced centers. In case of grade 2 hypothalamic involvement, we recommend to 287 
decrease the tumor size as much as possible before irradiation, with combined surgeries if 288 
necessary. For children and especially the youngest with isolated endocrine deficits and 289 
without visual impairment or signs of raised ICP, a close follow-up with MRI should be 290 
discussed, to gain time and postpone the time for irradiation (in case of hypothalamus 291 
involvement).  292 
 293 
Radiation therapy 294 
Radiation therapy is an effective means to achieve long-term disease control in children 295 
diagnosed with CP. Advances in radiation therapy including highly-focused methods of 296 
intensity-modulated photon and proton therapy have been used with more generalized target 297 
volume reduction strategies to improve the therapeutic ratio and increase the margin of safety 298 
72. Understanding that these patients present with significant co-morbidities and are subject to 299 
sometimes unavoidable effects of tumor and surgery prior to irradiation helps to balance 300 
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treatment recommendations and accept irradiation as a primary treatment modality with 301 
proper attribution of long-term effects. 302 
CP may be irradiated after neuroimaging diagnosis and without surgical intervention. 303 
Although these cases are uncommon, they comprise a unique group of patients that may be 304 
followed for radiation-related complications absent the contributions of other treatments. 305 
There are an increasing proportion of children treated with transnasal / transspenoidal surgery 306 
with goals similar to transcranial surgery - to decompress the tumor and improve or avoid 307 
symptoms – including attempted gross-total resection. The advantage of the transnasal 308 
approach has yet to be demonstrated in children who require irradiation; however, less 309 
invasive approach will create a new cohort of children to evaluate for outcomes and acute and 310 
late effects of treatment. Practical and early observations are concerns about the use of the 311 
transnasal approach in children with extensive and cystic tumors where unresected tumor may 312 
be prone to pseudotumor and cystic expansion during irradiation and necessitate transcranial 313 
intervention. That diabetes insipidus is generally accepted after transnasal surgery and might 314 
be avoided by transcranial approach is another consideration. Teams that lean toward less 315 
invasive surgery, so called “limited surgery” and radiation therapy consider the use of surgery 316 
(resection or catheter placement) to alleviate symptoms such as vision loss or other obvious 317 
neurological deficits, establish a diagnosis in the setting of equivocal neuroimaging 318 
assessment, and prevent symptoms when further progression might impact optic pathways, 319 
result in hydrocephalus, or compress neurological tissues such as the brainstem and increase 320 
the risks associated with irradiation. Indeed, surgery may be used to decrease the risks of 321 
irradiation when resection reduces the targeted volume, increases the distance between target 322 
and critical normal tissue structure or reduces mass effect, which might compromise tissues 323 
and increase the risk of severe complications including necrosis and vasculopathy.  324 
Target volumes for radiation therapy are best delineated by multiplanar, multisequence MR 325 
imaging. CT is required for radiation dose calculation and plays a vital role in the treatment 326 
planning process for the assurance that it provides when the calcified tumor is included in the 327 
targeted volume. The borders between tumor and normal tissue are usually distinct when not 328 
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interrupted by surgery including borders where invasion or attachment may be present or 329 
boundaries where invasion or attachment may be unlikely. 330 
In radiation oncology the gross tumor volume is defined as the residual tumor. In pediatric 331 
neuro-radiotherapy including the treatment of CP the gross tumor volume is often defined as 332 
the gross residual tumor and/or the tumor bed. When surgery is performed and portions of the 333 
tumor are resected or the borders of the tumor interrupted, the definition of the gross tumor 334 
volume relies on the post-operative imaging findings, a conversation between the surgeon and 335 
radiation oncologist, and experience and judgment of the radiation oncologist considering the 336 
advantages and disadvantages of limiting the extent of the targeted volume. Classic parallel-337 
opposed portals defined on planar x-ray imaging gave way to CT-based treatment planning 338 
more than 20 years ago. And while the earliest experience with conformal treatment planning 339 
irradiated relatively large margins of normal tissue surrounding the post-operative tumor 340 
complex, the move toward image-based treatment planning substantially reduced the amount 341 
of normal brain collaterally irradiated defining a new cohort of children for the evaluation of 342 
disease control and treatment related complications. The distinction between the two eras is 343 
important as late effects researchers focus on complications and the attribution of radiation to 344 
late effects in future patients. 345 
The clinical target volume margin – the anatomically defined margin surrounding the gross 346 
tumor volume – has varied considerably using photon therapy during the past two decades 347 
ranging from 2-10mm 73, 74 and depending on specific immobilization, verification, and 348 
delivery methods. The smallest target volume margins were used in highly-selected patients 349 
based on the physical limitations of the treatment devices and constrained to patients with 350 
small tumors < 6mm in diameter. More generalized conformal therapy methods including 351 
intensity-modulated photon therapy permitted treatment of larger tumors and the systematic 352 
study of target volume reduction. Understanding that the size and shape of the tumor may 353 
change during treatment in some patients and has made CP a leading indication for on-line 354 
and off-line imaging during irradiation including the use of MR imaging on a weekly basis or 355 
less often when imaging early in the treatment course demonstrates stability of the tumor 356 
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complex. The lack of cooperative or multi-institution clinical trials involving radiation 357 
therapy for CP has limited consensus on the appropriate target volume for irradiation; 358 
however, based on published reports and current listed trials the CTV margin for CP ranges 359 
from 3-5mm, most treating physicians will target both the post-operative tumor bed and 360 
residual tumor, and imaging at several time points during the treatment course and use image-361 
guidance regardless of the modality (Figure 3). 362 
There is a third aspect of basic clinical target volume definition that is now in evolution, the 363 
planning target volume. This margin surrounds the clinical target volume geometrically and is 364 
meant to account for variation in patient treatment set-up. Variability in patient set-up remains 365 
important for both photon and proton planning; however, the latter requires consideration of 366 
range uncertainty, which may vary on a beam by beam basis. Since very few beams are used 367 
with proton therapy and proton beams are more susceptible to changes in tissue path length 368 
robustness of proton treatment plans should include variability in target location as well as 369 
change in tissue composition and range calculation estimates. When prescribing proton 370 
therapy, there is an asymmetry to the final margin (planning target volume) that surrounds the 371 
previously defined clinical target volume.  372 
 373 
Adverse effects of radiation therapy 374 
The rationale for radiation therapy and its potential for side effects should be thoroughly 375 
understood by patients, their parents, and caregivers. Acute effects of radiation therapy are 376 
less concerning and when problematic related to treatment-induced cyst expansion. Most 377 
concerning is the broad impact of radiation therapy on cognitive function and the less 378 
common and potential more several complications vasculopathy and necrosis. The cognitive 379 
effects of radiation therapy are associated with patient age, sex, and key demographics as well 380 
as tumor and treatment-related factors 75 including the presence or absence of hydrocephalus 381 
that requires treatment, the extent of disease and resection, and radiation dose and volume. 382 
Similar to that observed following the treatment of other brain tumors, the impact of radiation 383 
therapy is greater in children under the age of 7-8 years and greatest in the very young. While 384 
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there is no limit concerning age at which irradiation may be administered in children with CP, 385 
the feasibility of surgery and other measures to delay or avoid irradiation should be 386 
considered for vulnerable patients. For those at increased risk for late effects, the most 387 
advanced forms of radiation therapy should be considered including pencil beam scanning 388 
proton therapy. 389 
CP has become one of the more common indications for proton therapy. Children with CP 390 
can be rigorously immobilized, a requirement for proton therapy, and the relatively central 391 
location of the tumor and homogeneous tissue path from surface to target reduces some of the 392 
physical uncertainties related to proton range. These uncertainties must be accounted for in 393 
the planning and delivery process. However, the sensitivity of protons to changes in tissue 394 
path length can be a cause for concern in patients who rapidly gain or lose weight during 395 
treatment or when the cystic components of the tumor dynamically change the size and shape 396 
of the target. Early adopters of proton therapy that used the passive scattering method of 397 
delivery noted a significant change in the volume of normal tissue that received the lowest 398 
doses and unclear (no change or even a slight increase) benefit in the volume of normal tissue 399 
adjacent to the target that received the highest doses. Newer methods of proton therapy 400 
known as pencil beam or discrete spot scanning employ a magnetically positioned beam that 401 
delivers spots of protons, and therefore dose, to successive layers of the tumor as planned by 402 
treatment planning software and delivered by the energy selection and control systems of the 403 
proton accelerator and associated hardware. The difference is a more robust but less 404 
conformal passive scattering method compared to a less robust and highly conformal pencil 405 
beam scanning method 76 that reduces dose both adjacent to and at a distance from the target. 406 
Additional uncertainties of proton therapy related to linear energy transfer and radiobiological 407 
effectiveness demand careful monitoring of both common and less common complications 408 
and comparison with highly annotated photon clinical datasets. There are emerging data 409 
suggesting the equivalence of proton therapy compared to photon therapy with regard to 410 
vasculopathy, necrosis, and general neurological sequelae 77. Investigators anticipate results 411 
supporting the hypothesis that cognitive outcomes are associated with radiation dose and 412 
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volume and that a reduction in critical combinations of radiation dose and volume achieved 413 
through the use of proton therapy will spare cognition in vulnerable patients.  414 
 415 
In conclusion, CP has been a leading indication for proton therapy in children 78. The ability 416 
of proton therapy to spare normal tissues from the volume that receives the lowest doses 417 
appears to be clear. That the reduction in the irradiated volume translates into improved 418 
outcomes for these patients remains uncertain and rests on the accumulation of prospective 419 
data assessing objective measures of CNS effects 79 and comparable patients treated with 420 
modern methods of photon irradiation. The results from early prospective trials should be 421 
available in 2017 [NCT01419067] (Table 2). 422 
 423 
Long-term sequelae and prognosis 424 
Patients with CP have a 3–19 fold higher cardiovascular mortality in comparison to the 425 
general population 7. 20–year overall survival is impaired in patients with hypothalamic 426 
involvement of CP 80, 81. Hypothalamic obesity has significant negative impact on long-term 427 
quality of survival 80, 82. Increased daytime sleepiness, fatigue, disturbances of circadian 428 
rhythms 83-86 and eating behaviour 87-89, gastrointestinal and pulmonary complaints (diarrhea, 429 
dyspnea) 80, memory deficits 90, 91, (neuro)endocrine deficiencies 92, non-alcoholic fatty liver 430 
disease 93, and neuropsychological imbalances 94-100 are major long-term side effects in CP 431 
patients with hypothalamic obesity. Sterkenburg et al. 80 recently reported that hypothalamic 432 
involvement had a significant negative impact on 20-yr overall survival. The degree of 433 
surgical resection had no effect on 20-yr progression free survival rate in CP, supporting the 434 
concept that gross-total resection was of no advantage in terms of tumour recurrence (Figure 435 
4). 436 
 437 
Treatment of hypothalamic obesity 438 
Due to disturbances in energy expenditure, central sympathetic output and appetite-439 
regulation, CP patients with hypothalamic obesity typically develop morbid obesity that is 440 
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mainly unresponsive to conventional lifestyle modifications 1, 101-103. Recent studies on novel 441 
pharmaceutical treatment options in CP patients with hypothalamic obesity report mixed 442 
results. Based on impairment of sympatho-adrenal activation and epinephrine production 443 
manifesting as a reduced hormonal response to hypoglycaemia, treating this disorder with 444 
amphetamine derivatives has been suggested 104. Zoicas et al 105 treated 8 adult patients (6 CP) 445 
with hypothalamic obesity with GLP-1 analogues and observed a substantial and sustained 446 
weight loss associated with improvements in metabolic and cardiovascular risk profiles. 447 
Daubenbüchel et al. 106 recently reported that CP patients are able to produce and secrete the 448 
hormone oxytocin, even when pituitary and hypothalamic structures were damaged. However, 449 
patients with hypothalamic damage grade 1, which involves damage only to the anterior 450 
hypothalamic areas, presented with a lower fasting level of oxytocin. In addition, changes in 451 
oxytocin levels before and after standardized breakfast correlated with BMI, demonstrating 452 
that CP patients with hypothalamic obesity show less variation in oxytocin secretion due to 453 
nutrition. Accordingly, the authors speculate that oxytocin supplementation might be a 454 
therapeutic option in CP patients with hypothalamic obesity and/or neurobehavioral deficits 455 
due to specific hypothalamic damage in the anterior hypothalamic area. 456 
Initial experiences with bariatric surgery in severely obese CP patients achieved sufficient 457 
tolerability and short-term weight reduction 107-109. An instant improvement of binge-eating 458 
behaviour in patients immediately after laparoscopic adjustable gastric banding (LAGB) was 459 
observed, but failed in long-term weight reduction. Treatment with invasive, non-reversible 460 
bariatric methods such as Roux-en-Y gastric bypass is most efficient in weight reducing 107 461 
but controversial in the paediatric population due to medical, ethical and legal considerations 462 
109. 463 
Despite the availability of promising therapeutic approaches 27, it must be emphasized that 464 
currently no generally accepted therapy for hypothalamic obesity in CP has been shown to be 465 
effective in randomized studies. 466 
 467 
Risk-adapted treatment strategies 468 
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Risk-adapted treatment strategies 53, 55, 96, 110-119 are focusing on the following main goals: (a) 469 
reversal of visual compression symptoms, (b) relief of raised intracranial pressure, (c) 470 
prevention of tumor regrowth/progression, and (d) restoration or substitution of pituitary 471 
hormone deficits plus all other supplement-supportive measures, while minimizing acute and 472 
long-term mortality and morbidity 1, 102, 120 (Table 3).  473 
De Vile et al. 121 published the first reports on the association between attempts at radical 474 
gross total resection in case of hypothalamic involvement and long-term morbidity. Puget et 475 
al. 53, 111 published an algorithm for surgical treatment of CP patients, which recommends a 476 
hypothalamus-sparing strategy based on a grading of hypothalamic tumor involvement in 477 
preoperative magnetic resonance imaging (MRI) 53. The same authors reported that patients 478 
neurosurgically treated according to this algorithm using a hypothalamus-sparing approach 479 
had similar relapse rates and a lower prevalence of severe obesity than patients treated by 480 
gross-total resection (28% versus 54%, respectively) 111. This was the first report in the 481 
literature proving the tolerability and efficacy of a hypothalamus-sparing strategy by 482 
comparing cohorts treated by the same experienced surgical team at a single institution, and 483 
thus eliminating the bias of surgical experience on outcome analysis. However, it is important 484 
to note that although the "hypothalamus-sparing surgery" increased the percentage of 485 
"normal" body mass index (BMI) from 17–38%, the likelihood of clinically significant weight 486 
gain remained 62% with nearly half of all patients developing morbid obesity. Müller et al. 487 
112, 113 published studies on a risk-adapted treatment strategy based on pre- and post-surgical 488 
grading of hypothalamic involvement/damage in MRI. The assessment of the suprasellar 489 
tumor extension towards the mammillary bodies is considered essential for their grading into 490 
anterior or posterior hypothalamic involvement/lesion. According to their report, patients with 491 
post-surgical lesions affecting posterior hypothalamic structures presented with increased 492 
BMI and reduced self-assessed quality of survival during long-term prospective follow-up 493 
(Figure 5). Mallucci et al. 55 published a treatment algorithm, suggesting a two-staged 494 
surgical approach with initial relief of cystic pressure and thereby down-staging the risk grade 495 
in appropriate cases.  496 
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Since the majority of patients in these studies come from low volume or low experience 497 
centers, the long-term outcome data may be more applicable to "community practice" than 498 
applicable to high volume surgical centers. Even though the Paris series 111 represents a large 499 
volume center, it is still a single institutional, sequential study and not multi institutional, 500 
randomized, or even case controlled. 501 
All of the above-mentioned treatment strategies and algorithms recommend that (a) for CP 502 
with hypothalamic involvement, limited surgical approaches and postoperative external 503 
irradiation are advisable, and (b) treatment of CP should be confined to experienced 504 
multidisciplinary teams.  505 
A major step towards potential standardization of preoperative staging in CP is the 506 
comparison of published grading systems for assessment of hypothalamic 507 
damage/involvement in regard to prediction value for severe hypothalamic obesity as the 508 
main sequelae impairing quality of survival. Mortini et al. 118 analyzed the sensitivity of three 509 
published grading systems 111-114 for prediction of hypothalamic obesity in their single center 510 
cohort. Variables identified as factors with high and comparable prediction value for 511 
postoperative hypothalamic syndrome were the degree of hypothalamic involvement 512 
according to the classification described by Sainte-Rose and Puget 111, Van Gompel et al. 114, 513 
and Muller et al. 112, 113. These results support the hypothesis that disease or treatment-related 514 
hypothalamic alterations have relevant negative impact on quality of survival and prognosis 515 
in CP 2, 122.   516 
There are only a few studies analyzing the prognosis of patients with CP in relation to the 517 
neurosurgeons’ experience 53, 112, 113, 123-126. Sanford 123 and Boop 124 reported clinically 518 
significant differences in outcome according to the neurosurgeons’ experience with the 519 
condition. Degree of obesity and quality of life were analyzed in a recent report based on 520 
reference assessment of tumor location and post-surgical hypothalamic lesions 113. Treatment 521 
was also analyzed regarding neurosurgical strategy and the neurosurgical center sizes based 522 
on patient load. Surgical lesions of anterior and posterior hypothalamic areas were associated 523 
with post-surgical obesity, negatively impacting long-term quality of survival in patients with 524 
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surgical posterior hypothalamic lesions 112, 113. Treatment strategies in large centers were less 525 
radical and the rates of complete resection and hypothalamic surgical lesions were lower than 526 
those of middle and small-sized centers 112, 113, 126. However, in multivariable analysis 527 
preoperative hypothalamic involvement was the only independent risk factor for severe 528 
obesity 113.  529 
For favourably localized CP, the preferred treatment of choice, especially at initial diagnosis, 530 
is an attempt at complete resection with preservation of hypothalamic and visual function 1, 531 
102, 111, 125, 127-130. For unfavourably localized tumours – those too close to or too entangled with 532 
the hypothalamus and/or the optic chiasm – a limited resection followed by irradiation should 533 
be considered in order to preserve integrity of and/or to avoid further damage to optic and 534 
hypothalamic structures 126, 131-138. 535 
Overall, surgical results reported by the most experienced /skilled surgeons after gross total 536 
removal of CPs (combining children and adults) coincide in an extremely low mortality (0-537 
5%) and low morbidity rates due to hypothalamic damage (around 10-15% on average). This 538 
is in apparent contradiction with the extreme heterogeneity regarding the pathological and 539 
clinical expression of these lesions and the common consideration of CPs as one of the most 540 
challenging lesions for the neurosurgeon in lectures as well as in personal communications. 541 
Everybody communicates dreadful experiences with individual CP cases, never reported in 542 
official journals. Surgical results should be improved with the learning curve effect (as 543 
reported by Yasargil et al. 47), but this effect seems negligible in recent publications. The 544 
honesty showed by the Necker’s team by changing their CP treatment paradigm to limit the 545 
surgical risks associate with hypothalamic injury must be appreciated.  546 
However, CPs represent the paradigm of an individual, multifaceted complex type of lesion 547 
which treatment should never be planned under the “rules” of a fixed protocol, independently 548 
of how experienced/skilled the team/surgeon/radiotherapist may be. In this sense, any 549 
approach of CPs as a “disease” or “common pathological entity” is misleading, as 550 
comparisons between series including lesions with different topographies, sizes, shapes, 551 
consistencies, histologies, clinical impairments, will not allow sound results nor warrant the 552 
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desired outcome for an individual patient. No proper characterization of the subset of 553 
adamantinomatous CPs in the children population versus the adult population has been 554 
provided up to date. However, given the rarity of these lesions it is the personal cautiousness 555 
and time inverted in gaining the maximal knowledge about every individual case, more than 556 
any dogmatic criteria established by a professional/political “authority” what makes the 557 
difference for each patient.  558 
 559 
Conclusions: 560 
In conclusion, the molecular pathogenesis of human adamantinomatous CP has started to be 561 
unveiled offering the possibility of testing novel treatments targeting pathogenic pathways. 562 
Several pre-clinical models are available, which although not perfect, are suitable tools to 563 
investigate the role of these pathways in tumour biology and determine their therapeutic 564 
potential against human adamantinomatous CP. 565 
Proton therapy clearly reduces collateral radiation dose to normal tissue when compared with 566 
photon (X-ray)-based methods of irradiation. Preliminary results from first generation trials 567 
using proton therapy are anticipated. 568 
Hopefully, published grading systems support efforts in establishing standards for staging in 569 
CP, which should be implemented by national and international societies. Gross-total 570 
resection should be avoided in CP with hypothalamic involvement to prevent further 571 
hypothalamic damage. As surgical expertise has been shown to have impact on postoperative 572 
morbidity, medical societies should establish criteria of adequate professional expertise for 573 
the treatment of CP. Based on these criteria, health authorities should organize the 574 
certification of centers of excellence authorized for treatment and care of patients with this 575 
chronic disease. 576 
 577 
Review criteria 578 
A search for original articles published between 2000 and 2016 that focused on childhood 579 
craniopharyngiomas was performed in PubMed, Science Citation Index Expanded, EMBASE 580 
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and Scopus. The search terms used were “craniopharyngioma”, “hypothalamus and obesity”, 581 
pituitary and obesity”, radiation oncology”, and “neurosurgery”. We also searched the 582 
reference lists of identified articles for further papers.  583 
 584 
Key points: 585 
• The clinical, neuroradiological and surgical definition of hypothalamic involvement is a 586 
fundamental factor related to postoperative poor outcome, progressive obesity and 587 
neuropsychological impairment in the child after surgical removal of CP. 588 
• There is a need to change the previously assumed “gold-standard” objective of a primary 589 
radical removal of the lesion in all cases by the new paradigm of a limited resection plus 590 
focused radiotherapy in CP patients with hypothalamic lesions.  591 
• Hypothalamic involvement and treatment-related hypothalamic lesions are associated with 592 
the highest risk of postoperative sequelae and impaired quality of survival. 593 
• Three dimensional intensity modulated proton beam radiotherapy has potential advantage of 594 
over photon beam methods to focus and limit the radiation effects to optic and hypothalamic 595 
structures. 596 
• Pre-clinical, in vivo mouse model of adamantinomatous CP have potential advantage to 597 
investigate the intracellular molecular pathways deregulated in the tumor and to test the use 598 
of specific drugs.   599 
 23
References 600 
 601 
1. Muller, H.L. Craniopharyngioma. Endocr Rev 35, 513-43 (2014). 602 
2. Muller, H.L. Consequences of craniopharyngioma surgery in children. J 603 
Clin Endocrinol Metab 96, 1981-91 (2011). 604 
3. Muller, H.L. Craniopharyngioma and hypothalamic injury: latest insights 605 
into consequent eating disorders and obesity. Curr Opin Endocrinol 606 
Diabetes Obes 23, 81-9 (2016). 607 
4. Muller, H.L. Risk-adapted treatment and follow-up management in 608 
childhood-onset craniopharyngioma. Expert Rev Neurother 16, 535-48 609 
(2016). 610 
5. Bunin, G.R. et al. The descriptive epidemiology of craniopharyngioma. J 611 
Neurosurg 89, 547-51 (1998). 612 
6. Olsson, D.S., Andersson, E., Bryngelsson, I.L., Nilsson, A.G. & Johannsson, G. 613 
Excess mortality and morbidity in patients with craniopharyngioma, 614 
especially in patients with childhood onset: a population-based study in 615 
Sweden. J Clin Endocrinol Metab 100, 467-74 (2015). 616 
7. Erfurth, E.M., Holmer, H. & Fjalldal, S.B. Mortality and morbidity in adult 617 
craniopharyngioma. Pituitary 16, 46-55 (2013). 618 
8. Muller, H.L. et al. Longitudinal study on growth and body mass index 619 
before and after diagnosis of childhood craniopharyngioma. J Clin 620 
Endocrinol Metab 89, 3298-305 (2004). 621 
9. Sklar, C.A. Craniopharyngioma: endocrine abnormalities at presentation. 622 
Pediatr Neurosurg 21 Suppl 1, 18-20 (1994). 623 
10. Hoffmann, A. et al. History before diagnosis in childhood 624 
craniopharyngioma: associations with initial presentation and long-term 625 
prognosis. Eur J Endocrinol 173, 853-62 (2015). 626 
11. Steno, J., Malacek, M. & Bizik, I. Tumor-third ventricular relationships in 627 
supradiaphragmatic craniopharyngiomas: correlation of morphological, 628 
magnetic resonance imaging, and operative findings. Neurosurgery 54, 629 
1051-58; discussion 1058-60 (2004). 630 
12. Prieto, R., Pascual, J.M. & Barrios, L. Optic chiasm distortions caused by 631 
craniopharyngiomas: clinical and magnetic resonance imaging correlation 632 
and influence on visual outcome. World Neurosurg 83, 500-29 (2015). 633 
13. Pascual, J.M., Prieto, R., Carrasco, R. & Barrios, L. Displacement of 634 
mammillary bodies by craniopharyngiomas involving the third ventricle: 635 
surgical-MRI correlation and use in topographical diagnosis. J Neurosurg 636 
119, 381-405 (2013). 637 
14. Saeki, N. et al. Heavily T2 weighted MR images of anterior optic pathways 638 
in patients with sellar and parasellar tumours - prediction of surgical 639 
anatomy. Acta Neurochir (Wien) 144, 25-35 (2002). 640 
15. Xie, T. et al. 3D-FIESTA MR images are useful in the evaluation of the 641 
endoscopic expanded endonasal approach for midline skull-base lesions. 642 
Acta Neurochir (Wien) 153, 12-8 (2011). 643 
16. Sekine, S. et al. Craniopharyngiomas of adamantinomatous type harbor 644 
beta-catenin gene mutations. Am J Pathol 161, 1997-2001 (2002). 645 
 24
17. Kato, K. et al. Possible linkage between specific histological structures and 646 
aberrant reactivation of the Wnt pathway in adamantinomatous 647 
craniopharyngioma. J Pathol 203, 814-21 (2004). 648 
18. Buslei, R. et al. Common mutations of beta-catenin in adamantinomatous 649 
craniopharyngiomas but not in other tumours originating from the sellar 650 
region. Acta Neuropathol 109, 589-97 (2005). 651 
19. Brastianos, P.K. et al. Exome sequencing identifies BRAF mutations in 652 
papillary craniopharyngiomas. Nature Genetics 46, 161-5 (2014). 653 
20. Holsken, A. et al. Adamantinomatous and papillary craniopharyngiomas 654 
are characterized by distinct epigenomic as well as mutational and 655 
transcriptomic profiles. Acta Neuropathol Commun 4, 20 (2016). 656 
21. Larkin, S.J., Preda, V., Karavitaki, N., Grossman, A. & Ansorge, O. BRAF 657 
V600E mutations are characteristic for papillary craniopharyngioma and 658 
may coexist with CTNNB1-mutated adamantinomatous 659 
craniopharyngioma. Acta Neuropathol (2014). 660 
22. Martinez-Barbera, J.P. & Buslei, R. Adamantinomatous 661 
craniopharyngioma: pathology, molecular genetics and mouse models. 662 
Journal of Pediatric Endocrinology and Metabolism 28, 7-17 (2015). 663 
23. Gaston-Massuet, C. et al. Increased Wingless (Wnt) signaling in pituitary 664 
progenitor/stem cells gives rise to pituitary tumors in mice and humans. 665 
Proceedings of the National Academy of Sciences of the United States of 666 
America 108, 11482-7 (2011). 667 
24. Holsken, A. et al. Target gene activation of the Wnt signaling pathway in 668 
nuclear beta-catenin accumulating cells of adamantinomatous 669 
craniopharyngiomas. Brain Pathol 19, 357-64 (2009). 670 
25. Preda, V., Larkin, S.J., Karavitaki, N., Ansorge, O. & Grossman, A.B. The Wnt 671 
signalling cascade and the adherens junction complex in 672 
craniopharyngioma tumorigenesis. Endocr Pathol 26, 1-8 (2015). 673 
26. Hofmann, B.M. et al. Nuclear beta-catenin accumulation as reliable marker 674 
for the differentiation between cystic craniopharyngiomas and rathke 675 
cleft cysts: a clinico-pathologic approach. Am J Surg Pathol 30, 1595-603 676 
(2006). 677 
27. Gump, J.M. et al. Identification of targets for rational pharmacological 678 
therapy in childhood craniopharyngioma. Acta Neuropathol Commun 3, 30 679 
(2015). 680 
28. Holsken, A., Buchfelder, M., Fahlbusch, R., Blumcke, I. & Buslei, R. Tumour 681 
cell migration in adamantinomatous craniopharyngiomas is promoted by 682 
activated Wnt-signalling. Acta Neuropathol 119, 631-9 (2010). 683 
29. Holsken, A. et al. EGFR signaling regulates tumor cell migration in 684 
craniopharyngiomas. Clinical Cancer Research 17, 4367-77 (2011). 685 
30. Stache, C. et al. Tight junction protein claudin-1 is differentially expressed 686 
in craniopharyngioma subtypes and indicates invasive tumor growth. 687 
Neuro Oncol 16, 256-64 (2014). 688 
31. Andoniadou, C.L. et al. Identification of novel pathways involved in the 689 
pathogenesis of human adamantinomatous craniopharyngioma. Acta 690 
Neuropathol 124, 259-71 (2012). 691 
32. Gomes, D.C. et al. Sonic Hedgehog pathway is upregulated in 692 
adamantinomatous craniopharyngiomas. European Journal of 693 
 25
Endocrinology / European Federation of Endocrine Societies 172, 603-8 694 
(2015). 695 
33. Gong, J. et al. High expression levels of CXCL12 and CXCR4 predict 696 
recurrence of adamanti-nomatous craniopharyngiomas in children. 697 
Cancer Biomark 14, 241-51 (2014). 698 
34. Martinez-Barbera, J.P. 60 YEARS OF NEUROENDOCRINOLOGY: Biology of 699 
human craniopharyngioma: lessons from mouse models. J Endocrinol 226, 700 
T161-72 (2015). 701 
35. Andoniadou, C.L. et al. Sox2(+) stem/progenitor cells in the adult mouse 702 
pituitary support organ homeostasis and have tumor-inducing potential. 703 
Cell Stem Cell 13, 433-45 (2013). 704 
36. Kode, A. et al. Leukaemogenesis induced by an activating beta-catenin 705 
mutation in osteoblasts. Nature 506, 240-4 (2014). 706 
37. Lujambio, A. et al. Non-cell-autonomous tumor suppression by p53. Cell 707 
153, 449-60 (2013). 708 
38. Bullard, D.E. & Bigner, D.D. Heterotransplantation of human 709 
craniopharyngiomas in athymic "nude" mice. Neurosurgery 4, 308-14 710 
(1979). 711 
39. Xu, J. et al. Angiogenesis and cell proliferation in human 712 
craniopharyngioma xenografts in nude mice. Journal of Neurosurgery 105, 713 
306-10 (2006). 714 
40. Stache, C. et al. Insights into the infiltrative behavior of 715 
adamantinomatous craniopharyngioma in a new xenotransplant mouse 716 
model. Brain Pathol 25, 1-10 (2015). 717 
41. Apps, J.R. et al. Imaging Invasion: Micro-CT imaging of adamantinomatous 718 
craniopharyngioma highlights cell type specific spatial relationships of 719 
tissue invasion. Acta Neuropathol Commun 4, 57 (2016). 720 
42. Pettorini, B.L. et al. The role of inflammation in the genesis of the cystic 721 
component of craniopharyngiomas. Childs Nervous System 26, 1779-84 722 
(2010). 723 
43. Stevens, A., Kloter, I. & Roggendorf, W. Inflammatory infiltrates and 724 
natural killer cell presence in human brain tumors. Cancer 61, 738-43 725 
(1988). 726 
44. Hoffman, H.J. et al. Aggressive surgical management of 727 
craniopharyngiomas in children. J Neurosurg 76, 47-52 (1992). 728 
45. Choux, M. & Lena, G. Bases of surgical management of craniopharyngioma 729 
in children [proceedings]. Acta Neurochir Suppl (Wien) 28, 348 (1979). 730 
46. Pierre-Kahn, A. et al. [Treatment of craniopharyngiomas in children. 731 
Retrospective analysis of 50 cases]. Arch Fr Pediatr 45, 163-7 (1988). 732 
47. Yasargil, M.G. et al. Total removal of craniopharyngiomas. Approaches and 733 
long-term results in 144 patients. J Neurosurg 73, 3-11 (1990). 734 
48. Caldarelli, M., di Rocco, C., Papacci, F. & Colosimo, C., Jr. Management of 735 
recurrent craniopharyngioma. Acta Neurochir (Wien) 140, 447-54 (1998). 736 
49. Zuccaro, G. Radical resection of craniopharyngioma. Childs Nerv Syst 21, 737 
679-90 (2005). 738 
50. DeVile, C.J., Grant, D.B., Hayward, R.D. & Stanhope, R. Growth and 739 
endocrine sequelae of craniopharyngioma. Arch Dis Child 75, 108-14 740 
(1996). 741 
 26
51. Muller, H.L. et al. Functional capacity and body mass index in patients 742 
with sellar masses--cross-sectional study on 403 patients diagnosed 743 
during childhood and adolescence. Childs Nerv Syst 21, 539-45 (2005). 744 
52. Muller, H.L. et al. Longitudinal study on quality of life in 102 survivors of 745 
childhood craniopharyngioma. Childs Nerv Syst 21, 975-80 (2005). 746 
53. Puget, S. et al. Pediatric craniopharyngiomas: classification and treatment 747 
according to the degree of hypothalamic involvement. J Neurosurg 106, 3-748 
12 (2007). 749 
54. Sainte-Rose, C. et al. Craniopharyngioma: the pendulum of surgical 750 
management. Childs Nerv Syst 21, 691-5 (2005). 751 
55. Mallucci, C. et al. Management of craniopharyngioma: the Liverpool 752 
experience following the introduction of the CCLG guidelines. Introducing 753 
a new risk assessment grading system. Childs Nerv Syst 28, 1181-92 754 
(2012). 755 
56. Bartels, U., Laperriere, N., Bouffet, E. & Drake, J. Intracystic therapies for 756 
cystic craniopharyngioma in childhood. Front Endocrinol (Lausanne) 3, 39 757 
(2012). 758 
57. Dastoli, P.A. et al. Cystic craniopharyngioma: intratumoral chemotherapy 759 
with alpha interferon. Arq Neuropsiquiatr 69, 50-5 (2011). 760 
58. Tatreau, J.R. et al. Anatomical considerations for endoscopic endonasal 761 
skull base surgery in pediatric patients. Laryngoscope 120, 1730-7 762 
(2010). 763 
59. Ali, Z.S. et al. Suprasellar pediatric craniopharyngioma resection via 764 
endonasal endoscopic approach. Childs Nerv Syst 29, 2065-70 (2013). 765 
60. Campbell, P.G. et al. Endocrinological and ophthalmological consequences 766 
of an initial endonasal endoscopic approach for resection of 767 
craniopharyngiomas. Neurosurg Focus 28, E8 (2010). 768 
61. Locatelli, D. et al. Endoscopic endonasal transsphenoidal surgery for sellar 769 
tumors in children. Int J Pediatr Otorhinolaryngol 74, 1298-302 (2010). 770 
62. Fahlbusch, R., Honegger, J., Paulus, W., Huk, W. & Buchfelder, M. Surgical 771 
treatment of craniopharyngiomas: experience with 168 patients. J 772 
Neurosurg 90, 237-50 (1999). 773 
63. Zona, G. & Spaziante, R. Management of cystic craniopharyngiomas in 774 
childhood by a transsphenoidal approach. J Pediatr Endocrinol Metab 19 775 
Suppl 1, 381-8 (2006). 776 
64. Elliott, R.E., Jane, J.A., Jr. & Wisoff, J.H. Surgical management of 777 
craniopharyngiomas in children: meta-analysis and comparison of 778 
transcranial and transsphenoidal approaches. Neurosurgery 69, 630-43; 779 
discussion 643 (2011). 780 
65. Prieto, R. et al. Predictive factors for craniopharyngioma recurrence: a 781 
systematic review and illustrative case report of a rapid recurrence. 782 
World Neurosurg 79, 733-49 (2013). 783 
66. Steno, J. Microsurgical topography of craniopharyngiomas. Acta Neurochir 784 
Suppl (Wien) 35, 94-100 (1985). 785 
67. Pascual, J.M., Prieto, R. & Carrasco, R. Infundibulo-tuberal or not strictly 786 
intraventricular craniopharyngioma: evidence for a major topographical 787 
category. Acta Neurochir (Wien) 153, 2403-25; discussion 2426 (2011). 788 
 27
68. Pan, J. et al. Intraventricular craniopharyngioma: morphological analysis 789 
and outcome evaluation of 17 cases. Acta Neurochir (Wien) 153, 773-84 790 
(2011). 791 
69. Qi, S. et al. Anatomic relations of the arachnoidea around the pituitary 792 
stalk: relevance for surgical removal of craniopharyngiomas. Acta 793 
Neurochir (Wien) 153, 785-96 (2011). 794 
70. Tomita, T. & Bowman, R.M. Craniopharyngiomas in children: surgical 795 
experience at Children's Memorial Hospital. Childs Nerv Syst 21, 729-46 796 
(2005). 797 
71. Wang, K.C., Hong, S.H., Kim, S.K. & Cho, B.K. Origin of craniopharyngiomas: 798 
implication on the growth pattern. Childs Nerv Syst 21, 628-34 (2005). 799 
72. Kiehna, E.N. & Merchant, T.E. Radiation therapy for pediatric 800 
craniopharyngioma. Neurosurg Focus 28, E10 (2010). 801 
73. Dunbar, S.F. et al. Stereotactic radiotherapy for pediatric and adult brain 802 
tumors: preliminary report. Int J Radiat Oncol Biol Phys 30, 531-9 (1994). 803 
74. Merchant, T.E. et al. Disease control after reduced volume conformal and 804 
intensity modulated radiation therapy for childhood craniopharyngioma. 805 
Int J Radiat Oncol Biol Phys 85, e187-92 (2013). 806 
75. Di Pinto, M., Conklin, H.M., Li, C. & Merchant, T.E. Learning and memory 807 
following conformal radiation therapy for pediatric craniopharyngioma 808 
and low-grade glioma. Int J Radiat Oncol Biol Phys 84, e363-9 (2012). 809 
76. Beltran, C., Roca, M. & Merchant, T.E. On the benefits and risks of proton 810 
therapy in pediatric craniopharyngioma. Int J Radiat Oncol Biol Phys 82, 811 
e281-7 (2012). 812 
77. Merchant, T.E. et al. Necrosis, vasculopathy, neurological complications 813 
after proton therapy for childhood craniopharyngioma: Results from a 814 
prospective trial and a photn cohort comparison. Proc of the American 815 
Society for Radiation Oncology, 57th Annual Meeting, to be published 816 
September 21, 2016 817 
78. Bishop, A.J. et al. Proton beam therapy versus conformal photon radiation 818 
therapy for childhood craniopharyngioma: multi-institutional analysis of 819 
outcomes, cyst dynamics, and toxicity. Int J Radiat Oncol Biol Phys 90, 354-820 
61 (2014). 821 
79. Uh, J. et al. Effects of Surgery and Proton Therapy on Cerebral White 822 
Matter of Craniopharyngioma Patients. Int J Radiat Oncol Biol Phys 93, 64-823 
71 (2015). 824 
80. Sterkenburg, A.S. et al. Survival, hypothalamic obesity, and 825 
neuropsychological/psychosocial status after childhood-onset 826 
craniopharyngioma: newly reported long-term outcomes. Neuro Oncol 17, 827 
1029-38 (2015). 828 
81. Daubenbuchel, A.M. et al. Hydrocephalus and hypothalamic involvement 829 
in pediatric patients with craniopharyngioma or cysts of Rathke's pouch: 830 
impact on long-term prognosis. Eur J Endocrinol 172, 561-9 (2015). 831 
82. Karavitaki, N. et al. Craniopharyngiomas in children and adults: 832 
systematic analysis of 121 cases with long-term follow-up. Clin Endocrinol 833 
(Oxf) 62, 397-409 (2005). 834 
83. Pickering, L. et al. Sleep-wake and melatonin pattern in 835 
craniopharyngioma patients. Eur J Endocrinol 170, 873-84 (2014). 836 
 28
84. Muller, H.L. Increased daytime sleepiness in patients with childhood 837 
craniopharyngioma and hypothalamic tumor involvement: review of the 838 
literature and perspectives. Int J Endocrinol 2010, 519607 (2010). 839 
85. Muller, H.L. et al. Melatonin treatment in obese patients with childhood 840 
craniopharyngioma and increased daytime sleepiness. Cancer Causes 841 
Control 17, 583-9 (2006). 842 
86. Romijn, J.A. Pituitary diseases and sleep disorders. Curr Opin Endocrinol 843 
Diabetes Obes 23, 345-51 (2016). 844 
87. Hoffmann, A., Postma, F.P., Sterkenburg, A.S., Gebhardt, U. & Muller, H.L. 845 
Eating behavior, weight problems and eating disorders in 101 long-term 846 
survivors of childhood-onset craniopharyngioma. J Pediatr Endocrinol 847 
Metab 28, 35-43 (2015). 848 
88. Heymsfield, S.B. et al. Hyperphagia: current concepts and future 849 
directions proceedings of the 2nd international conference on 850 
hyperphagia. Obesity (Silver Spring) 22 Suppl 1, S1-S17 (2014). 851 
89. Roth, C.L. et al. Functional neuroimaging in craniopharyngioma: a useful 852 
tool to better understand hypothalamic obesity? Obes Facts 5, 243-53 853 
(2012). 854 
90. Ozyurt, J. et al. Neuropsychological outcome in patients with childhood 855 
craniopharyngioma and hypothalamic involvement. J Pediatr 164, 876-856 
881 e4 (2014). 857 
91. Ozyurt, J. et al. Remote effects of hypothalamic lesions in the prefrontal 858 
cortex of craniopharygioma patients. Neurobiol Learn Mem 111, 71-80 859 
(2014). 860 
92. Honegger, J., Buchfelder, M. & Fahlbusch, R. Surgical treatment of 861 
craniopharyngiomas: endocrinological results. J Neurosurg 90, 251-7 862 
(1999). 863 
93. Hoffmann, A. et al. Nonalcoholic fatty liver disease and fatigue in long-864 
term survivors of childhood-onset craniopharyngioma. Eur J Endocrinol 865 
173, 389-97 (2015). 866 
94. Roemmler-Zehrer, J. et al. Specific behaviour, mood and personality traits 867 
may contribute to obesity in patients with craniopharyngioma. Clin 868 
Endocrinol (Oxf) 82, 106-14 (2015). 869 
95. Zada, G., Kintz, N., Pulido, M. & Amezcua, L. Prevalence of 870 
neurobehavioral, social, and emotional dysfunction in patients treated for 871 
childhood craniopharyngioma: a systematic literature review. PLoS One 8, 872 
e76562 (2013). 873 
96. Fjalldal, S. et al. Hypothalamic Involvement Predicts Cognitive 874 
Performance and Psychosocial Health in Long-term Survivors of 875 
Childhood Craniopharyngioma. J Clin Endocrinol Metab 98, 3253-62 876 
(2013). 877 
97. Crespo, I., Santos, A. & Webb, S.M. Quality of life in patients with 878 
hypopituitarism. Curr Opin Endocrinol Diabetes Obes 22, 306-12 (2015). 879 
98. Crespo, I., Valassi, E., Santos, A. & Webb, S.M. Health-related quality of life 880 
in pituitary diseases. Endocrinol Metab Clin North Am 44, 161-70 (2015). 881 
99. Ozyurt, J., Muller, H.L. & Thiel, C.M. A systematic review of cognitive 882 
performance in patients with childhood craniopharyngioma. J Neurooncol 883 
125, 9-21 (2015). 884 
 29
100. Pereira, A.M. et al. High prevalence of long-term cardiovascular, 885 
neurological and psychosocial morbidity after treatment for 886 
craniopharyngioma. Clin Endocrinol (Oxf) 62, 197-204 (2005). 887 
101. Haliloglu, B. & Bereket, A. Hypothalamic obesity in children: 888 
pathophysiology to clinical management. J Pediatr Endocrinol Metab 28, 889 
503-13 (2015). 890 
102. Muller, H.L. Paediatrics: surgical strategy and quality of life in 891 
craniopharyngioma. Nat Rev Endocrinol 9, 447-9 (2013). 892 
103. Muller, H.L. Risk-adapted, long-term management in childhood-onset 893 
craniopharyngioma. Pituitary (2016). 894 
104. Elfers, C.T. & Roth, C.L. Effects of methylphenidate on weight gain and 895 
food intake in hypothalamic obesity. Front Endocrinol (Lausanne) 2, 78 896 
(2011). 897 
105. Zoicas, F., Droste, M., Mayr, B., Buchfelder, M. & Schofl, C. GLP-1 analogues 898 
as a new treatment option for hypothalamic obesity in adults: report of 899 
nine cases. Eur J Endocrinol 168, 699-706 (2013). 900 
106. Daubenbuchel, A.M. et al. Oxytocin in survivors of childhood-onset 901 
craniopharyngioma. Endocrine (2016). 902 
107. Bretault, M. et al. Clinical review: Bariatric surgery following treatment 903 
for craniopharyngioma: a systematic review and individual-level data 904 
meta-analysis. J Clin Endocrinol Metab 98, 2239-46 (2013). 905 
108. Gatta, B. et al. Is bariatric surgery really inefficient in hypothalamic 906 
obesity? Clin Endocrinol (Oxf) 78, 636-8 (2013). 907 
109. Muller, H.L., Gebhardt, U., Maroske, J. & Hanisch, E. Long-term follow-up of 908 
morbidly obese patients with childhood craniopharyngioma after 909 
laparoscopic adjustable gastric banding (LAGB). Klin Padiatr 223, 372-3 910 
(2011). 911 
110. de Vile, C.J. et al. Obesity in childhood craniopharyngioma: relation to 912 
post-operative hypothalamic damage shown by magnetic resonance 913 
imaging. J Clin Endocrinol Metab 81, 2734-7 (1996). 914 
111. Elowe-Gruau, E. et al. Childhood craniopharyngioma: hypothalamus-915 
sparing surgery decreases the risk of obesity. J Clin Endocrinol Metab 98, 916 
2376-82 (2013). 917 
112. Muller, H.L. et al. Xanthogranuloma, Rathke's cyst, and childhood 918 
craniopharyngioma: results of prospective multinational studies of 919 
children and adolescents with rare sellar malformations. J Clin Endocrinol 920 
Metab 97, 3935-43 (2012). 921 
113. Muller, H.L. et al. Post-operative hypothalamic lesions and obesity in 922 
childhood craniopharyngioma: results of the multinational prospective 923 
trial KRANIOPHARYNGEOM 2000 after 3-year follow-up. Eur J Endocrinol 924 
165, 17-24 (2011). 925 
114. Van Gompel, J.J., Nippoldt, T.B., Higgins, D.M. & Meyer, F.B. Magnetic 926 
resonance imaging-graded hypothalamic compression in surgically 927 
treated adult craniopharyngiomas determining postoperative obesity. 928 
Neurosurg Focus 28, E3 (2010). 929 
115. Elliott, R.E., Sands, S.A., Strom, R.G. & Wisoff, J.H. Craniopharyngioma 930 
Clinical Status Scale: a standardized metric of preoperative function and 931 
posttreatment outcome. Neurosurg Focus 28, E2 (2010). 932 
 30
116. Steno, J., Bizik, I., Steno, A. & Matejcik, V. Craniopharyngiomas in children: 933 
how radical should the surgeon be? Childs Nerv Syst 27, 41-54 (2011). 934 
117. Roth, C.L. et al. Semiquantitative analysis of hypothalamic damage on MRI 935 
predicts risk for hypothalamic obesity. Obesity (Silver Spring) 23, 1226-33 936 
(2015). 937 
118. Mortini, P. et al. Magnetic resonance imaging as predictor of functional 938 
outcome in craniopharyngiomas. Endocrine 51, 148-62 (2016). 939 
119. Garre, M.L. & Cama, A. Craniopharyngioma: modern concepts in 940 
pathogenesis and treatment. Curr Opin Pediatr 19, 471-9 (2007). 941 
120. Muller, H.L. Childhood craniopharyngioma--current concepts in diagnosis, 942 
therapy and follow-up. Nat Rev Endocrinol 6, 609-18 (2010). 943 
121. De Vile, C.J. et al. Management of childhood craniopharyngioma: can the 944 
morbidity of radical surgery be predicted? J Neurosurg 85, 73-81 (1996). 945 
122. Muller, H.L. Craniopharyngioma: long-term consequences of a chronic 946 
disease. Expert Rev Neurother 15, 1241-4 (2015). 947 
123. Sanford, R.A. Craniopharyngioma: results of survey of the American 948 
Society of Pediatric Neurosurgery. Pediatr Neurosurg 21 Suppl 1, 39-43 949 
(1994). 950 
124. Boop, F.A. Craniopharyngioma. J Neurosurg 106, 1-2; discussion 2 (2007). 951 
125. Hankinson, T.C. et al. Patterns of care for craniopharyngioma: survey of 952 
members of the american association of neurological surgeons. Pediatr 953 
Neurosurg 49, 131-6 (2013). 954 
126. Hoffmann, A. et al. Childhood craniopharyngioma - changes of treatment 955 
strategies in the trials KRANIOPHARYNGEOM 2000/2007. Klin Padiatr 956 
226, 161-8 (2014). 957 
127. Rath, S.R. et al. Childhood craniopharyngioma: 20-year institutional 958 
experience in Western Australia. J Paediatr Child Health 49, 403-8 (2013). 959 
128. Lo, A.C. et al. Long-term outcomes and complications in patients with 960 
craniopharyngioma: the British Columbia Cancer Agency experience. Int J 961 
Radiat Oncol Biol Phys 88, 1011-8 (2014). 962 
129. Zaidi, H.A., Chapple, K. & Little, A.S. National treatment trends, 963 
complications, and predictors of in-hospital charges for the surgical 964 
management of craniopharyngiomas in adults from 2007 to 2011. 965 
Neurosurg Focus 37, E6 (2014). 966 
130. Muller, H.L. Childhood craniopharyngioma: treatment strategies and 967 
outcomes. Expert Rev Neurother 14, 187-97 (2014). 968 
131. Flitsch, J., Aberle, J. & Burkhardt, T. Surgery for pediatric 969 
craniopharyngiomas: is less more? J Pediatr Endocrinol Metab 28, 27-33 970 
(2015). 971 
132. Buchfelder, M., Schlaffer, S.M., Lin, F. & Kleindienst, A. Surgery for 972 
craniopharyngioma. Pituitary 16, 18-25 (2013). 973 
133. Mortini, P., Gagliardi, F., Boari, N. & Losa, M. Surgical strategies and 974 
modern therapeutic options in the treatment of craniopharyngiomas. Crit 975 
Rev Oncol Hematol 88, 514-29 (2013). 976 
134. Ali, Z.S. et al. Comparative effectiveness of treatment options for pediatric 977 
craniopharyngiomas. J Neurosurg Pediatr 13, 178-88 (2014). 978 
135. Ogawa, Y., Kawaguchi, T. & Tominaga, T. Outcome and mid-term 979 
prognosis after maximum and radical removal of craniopharyngiomas 980 
 31
with the priority to the extended transsphenoidal approach--a single 981 
center experience. Clin Neurol Neurosurg 125, 41-6 (2014). 982 
136. Raza, S.M. & Schwartz, T.H. How to achieve the best possible outcomes in 983 
the management of retroinfundibular craniopharyngiomas? World 984 
Neurosurg 82, 614-6 (2014). 985 
137. Daubenbuchel, A.M. & Muller, H.L. Neuroendocrine Disorders in Pediatric 986 
Craniopharyngioma Patients. J Clin Med 4, 389-413 (2015). 987 
138. Flitsch, J., Muller, H.L. & Burkhardt, T. Surgical strategies in childhood 988 
craniopharyngioma. Front Endocrinol (Lausanne) 2, 96 (2011). 989 
 990 
 991 
Figure 1 1 
Genes and molecular pathways involved in human ACP. Schematic outlining majorly 2 
deregulated genes and pathways in ACP, resulting from activating mutations in beta-catenin. 3 
Most, if not all ACP tumours carry mutations in CTNNB1 (beta-catenin) directly resulting in 4 
the over-activation of the WNT/beta-catenin pathway. This is evidenced by the expression of 5 
target genes such as AXIN2 and LEF1. As the result of this initial oncogenic hit, defined as 6 
the driver mutation, several further genes and pathways become deregulated. These are likely 7 
to affect multiple biological processes such as cell proliferation, survival, differentiation, 8 
inflammation, angiogenesis, cell adhesion and tumour infiltration among others. The colour 9 
code indicates the potential involvement of the deregulated pathways in these biological 10 
processes, as deducted from other cellular/tumoural contexts. This assessment is not exclusive 11 
as many of the pathways may be involved either directly or indirectly in several or all of the 12 
processes indicated. Knowing whether the inhibition or stimulation of some of these pathways 13 
may be of therapeutic use requires robust pre-clinical data to confirm their pathogenic effects. 14 
For more details, see references 20, 24, 27, 30-33  15 

Figure 2:  1 
Paracrine model for the involvement of pituitary stem cells in tumorigenesis. (i) Schematic 2 
representation of Sox2+ve stem cells (A) and Sox2-ve cells in the adult pituitary. Expression of 3 
oncogenic β-catenin in some Sox2+ve cells (A* in ii) results in transient proliferation and 4 
formation of β-catenin-accumulating cell clusters (A* in iii-vi) and the release of secreted factors 5 
to the surrounding cells (iii) leading to cell transformation (B’), proliferation (B’ in v) and tumour 6 
formation (B’ in vi).  7 

Figure 3 1 
The figure shows an image of a sagittal CT with color-wash proton dose distribution in a child with 2 
craniopharyngioma. Bone defect present in base of skull after trans-nasal surgery and calcifications 3 
present in third ventricle corresponding to unresected tumor. Color legend: orange-red = 50.4-54CGE; 4 
dark blue ≤ 10.8CGE. 5 
Figure 3 
Figure 4 1 
Twenty-yr overall survival in regard to hypothalamic involvement (Figure 4A) and 20-yr progression-2 
free survival (PFS) in regard to the degree of surgical resection (Figure 4B) of patients with childhood-3 
onset craniopharyngioma recruited in the trial HIT Endo. CR=complete resection; IR=incomplete 4 
resection; as confirmed by neuroradiological reference assessment. Reproduced and modified from 5 
Sterkenburg et al. 80 with kind permission of Oxford University Press. 6 
no HI, n = 82 (0.95 ± 0.04) 
HI, n = 132 (0.84 ± 0.04) 
p=0.006 
95%-CI: 
no HI: 0.87 – 1.0 
HI: 0.76 – 0.92 
Figure 4A 
IR, n = 87 (0.65 ± 0.08) 
CR, n = 65 (0.48 ± 0.15) 
95%-CI: 
CR: 0.19 – 0.78 
IR: 0.49 – 0.81 p=0.722 
Figure 4B 
Figure 5 1 
BMI and MRI imaging at diagnosis and 36 months after surgery in three cases of childhood 2 
craniopharyngiomas (CP) with different grade of hypothalamic involvement/lesion. (a and b) Patient 3 
with CP confined to the intrasellar space (0o no hypothalamic involvement (a)/surgical lesion (b)). 4 
BMI at diagnosis: –1.96 S.D.; BMI 36 months after complete resection: –1.62 S.D. (c and d) Patient 5 
with CP involving the anterior hypothalamus (Io hypothalamic involvement (c)/surgical lesion of the 6 
anterior hypothalamic area (d)). BMI at diagnosis: +1.01 S.D.; BMI 36 months after complete 7 
resection: +0.59 S.D. (e and f) Patient with CP involving the anterior and posterior hypothalamus (II0 8 
hypothalamic involvement (e)/surgical lesion of the anterior and posterior hypothalamic area (f)). BMI 9 
at diagnosis: +6.08 S.D.; BMI 36 months after complete resection: +6.79 S.D. Mammillary bodies are 10 
defining the border between anterior and posterior involvement/lesion. Figure 3 e,f modified and 11 
reproduced from Müller et al. 113 with permission of Bioscientifica. 12 
a b 
c d 
e f 
Figure 5 
Table 1 1 
Comparison of available pre-clinical models of human adamantinomatous craniopharyngioma. 2 
GEMMs: Genetically modified mouse models; PDXs: Patient-derived xenografts; Origin: The origin 3 
of the tumour cells; Availability: Primary cells are not immortalized, so as PDXs, availability is 4 
restricted to biopsies, which are rare; Tumour location: GEMMs‘ tumours develop intracranially. 5 
PDXs have been generated intracranially and subcutaneously; Growth: PDXs and primary cells show 6 
very slow growth; Cellular architecture: GEMMs’ tumours show only some histological similarities to 7 
human ACP, whilst PDXs are identical to the human neoplasias; Brain Blood Barrier (BBB): 8 
GEMMs’ tumours develop outside the BBB. PDXs’ tumours grow either within (e.g. cortex) or 9 
outside (e.g. subcutaneously) the BBB; Tumour/host interactions: PDXs develop in 10 
immunosuppressed mice. 11 
 Table 1 
Comparison of available pre-clinical models of human adamantinomatous 
craniopharyngioma. 
 
 Primary cells GEMMs PDXs 
Origin Human Mouse Human 
Availability  Difficult Easy Difficult 
Tumour location  - Orthotopic Orthotopic/heterotopic 
Growth Slow Fast Slow 
Preserved cellular 
architecture 
- Partial Identical 
BBB penetrance 
problems 
- No Yes/No 
Tumour/host interactions - Yes No 
 
Table 2 1 
Advantages and disadvantages of modern radiotherapy methods used in the treatment of 2 
craniopharyngioma 3 
Table 2 
 
 
Technology  Advantages  Disadvantages  
Conventional 2-D radiotherapy  Reliable clinical data and long-term follow-up indicating high efficacy of radiotherapy.  
Poor geometrical precision. No reliable protection of 
normal surrounding tissues. 
Fractionated conformal radiation 
therapy/IMRT  
 
Widely available, highly conformal, ease in 
adapting treatment to changing target.   
Highly conformal photon therapy requires exposure of a 
larger volume of normal tissue to low doses of radiation.  
Fractionated proton therapy 
Normal tissue sparing. The volume or normal 
tissues exposed to low doses is significantly 
less compared to fractionated photon 
methods. 
Limited experience and significant costs. Image-guidance 
systems have lagged. Early passive scattering systems 
provided robust treatment yet lacked conformity of 
advanced photon systems. Newer pencil beam scanning 
systems require evaluation in clinical trials.  
Radiosurgery  Single treatment session. Highly conformal. Almost no dose to non-target tissue.  
Limited indications and experience. Only suitable for 
small volume solid residual and when tumor is not in 
contact with vital structures such as optic chiasm. 
Hypofractionated image guided  
radiosurgery (CyberKnife)  
Fewer treatment sessions. Highly conformal.. 
May have biological advantages under 
certain conditions.  
Very limited indications and experience. Role still unclear. 
No reliable data for tumor control or side effect reduction. 
Intracavitary colloid isotope application  
High tumor control rates for cystic 
components. Applicable to tumors recurrent 
after prior irradiation.  
Advantages limited to cystic tumors. Underdosage of 
solid components. Complications related to leakage or 
high-doses when administered in proximity to vital 
structures such as visual pathways and brainstem. 
   
 
Table 3 1 
Novel grading systems and treatment algorithms for craniopharyngioma patients based on magnetic 2 
resonance imaging. n, size of cohort; FU, follow-up; HI, hypothalamic involvement; HD, 3 
hypothalamic damage; n.a., not analyzed; HUI, Health Utility Index; GTR, gross-total resection; STR, 4 
subtotal resection; MB, mammillary bodies; XRT, irradiation; BMI, body mass index; TGTV, growth 5 
towards 3rd ventricle; MRI, magnetic resonance imaging; w/o, without; ped, pediatric patients. 6 
Table 3: 
 
Author  n FU 
(yr) 
Grade 
0 (0o) 
Grade 1
(Io)
Grade 2
(IIo)
Treatment recommendation Outcome parameters 
Puget53 66 
ped 
7 No HI Contact with HI (distortion/ 
elevation) the hypothalamus 
is still visible 
Tumor spread to the 
hypothalamus, which was 
no longer identifiable. 
0o: GTR
Io: GTR; if not achieved: 2nd OP ± XRT
IIo: STR w/o HD + XRT 
Grading correlated with 
BMI, HUI, neuropsycho-
logical disorders 
Elowe-
Gruau111 
65 
ped 
3 No HI 
 
Contact with HI (distortion/ 
elevation) the hypothalamus 
is still visible 
Tumor spread to the 
hypothalamus, which was 
no longer identifiable. 
0o: GTR
Io: GTR; if not achieved: 2nd OP ± XRT
IIo: STR w/o HD + XRT
Lower BMI in cohort 
treated per algorithm  
Müller 
112, 113  
120 
ped 
3 No HI 
 
HI/HD of the anterior 
hypothalamus not 
involving MB 
HI/HD of the anterior + 
posterior hypothalamic 
area, i.e., involving MB 
0o: GTR
Io: STR w/o HD + XRT 
IIo: STR w/o HD + XRT
Higher BMI and lower 
QoL in IIo cohort treated 
by GTR with posterior HD 
Fjalldal 
96  
42 
ped 
20 No HI 
 
Suprasellar growth, not  
towards or into the 3rd 
ventricle (non-TGTV)
Suprasellar growth 
towards or into the 3rd 
ventricle (TGTV)
Non-TGTV: GTR
TGTV: STR w/o HD + XRT 
Lower cognitive 
performance in TGTV 
patients treated by GTR 
Van 
Gompel114 
28 
 adults 
1 No HI Degree of hypothalamic T2 signal change and irregular 
hypothalamic contrast enhancement in MRI 
Risk-adapted surgical strategies 
according to MRI findings on HI 
Post-OP weight gain corre-
lated with degree of HI 
Elliott115 80 
ped 
9 Preoperative clinical status assessed with standardized scale (CCSS) 
including vision, pituitary function, hypothalamic dysfunction, 
educational/occupational status
Risk-adapted surgical strategies 
according to preoperative CCSS 
findings
Pre-OP CCSS predicted 
outcome better than MRI-
assessed HI/HD
Steno116 41 
ped 
10 No HI Outside the 3rd ventricle Inside the 3rd ventricle GTR only in case of location outside 
the 3rd ventricle recommended
Better outcome after GTR 
in extraventricular cases  
Mallucci 
55 
20 
ped 
3 No HI 
 
Tumor size (<2–4cm), no 
hydrocephalus, no breech 
3rd ventricle
Retrochiasmatic tumor, 
(>4cm), hydrocephalus, 
breech 3rd ventricle  
0o: GTR
Io: consider GTR 
IIo: STR w/o HD + XRT
Reassessment of HI after 
endoscopic cyst shrinkage, 
improved surgical strategy 
Roth117 41 
ped 
5 No HI HD score including assessment of pituitary gland and 
stalk, ventriculomegaly, and residual tumor
Risk-adapted surgical strategies 
according to HD score
HD score correlated 
(p=0.02) with BMI post OP 
Mortini 
118 
47 
20% 
ped 
3.2 Grade of HI according to hypothalamic hyperintensity in T2-weigh-
ted MRI, MB involvement, unidentifiable pituitary stalk, dislocated 
chiasm, unrecognizable supraoptic recess, retrochiasmatic extension
Risk-adapted surgical strategies 
according to grade of HI 
Outcome related (p<0.01) 
to published grading 
systems 53, 112, 113
 
 
